Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 8/20 | 0.61 |
| ▸ | CTSL | P07711 | 8/20 | 0.60 |
| ▸ | CTSB | P07858 | 4/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549655 | 0.92 | CAPN1 (0.66) | CAPN1CTSKCTSLCTSBPSMB1 | |
| SCHEMBL29372797 | 0.92 | CAPN1 (0.66) | CAPN1CTSKCTSLCTSBPSMB1 | |
| SCHEMBL14513399 | 0.92 | CAPN1 (0.66) | CAPN1CTSKCTSLCTSBPSMB1 | |
| SCHEMBL5805898 | 0.91 | CAPN1 (0.63) | CAPN1CTSKCTSLCTSBCTSS | |
| Water SCHEMBL29578866 | 0.91 | CAPN1 (0.65) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL6276287 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL14148469 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL6482122 | 0.89 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL29577873 | 0.88 | CAPN1 (0.60) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL931659 | 0.87 | CAPN1 (0.69) | CAPN1CTSKCTSLCTSBHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | CAPN1 4143/4885CTSK 711/4885CTSL 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.